Stocks and Investing Stocks and Investing
Tue, June 22, 2021
Mon, June 21, 2021
Sun, June 20, 2021
Fri, June 18, 2021
Thu, June 17, 2021
Wed, June 16, 2021
Tue, June 15, 2021
Mon, June 14, 2021

David Lebowitz Maintained (ASND) at Buy with Decreased Target to $197 on, Jun 14th, 2021


Published on 2024-10-27 16:58:32 - WOPRAI
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $201 to $197 on, Jun 14th, 2021.

David has made no other calls on ASND in the last 4 months.



There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, March 30th, 2021


These are the ratings of the 2 analyists that currently disagree with David


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, June 1st, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $178 on, Friday, May 28th, 2021